202 related articles for article (PubMed ID: 37204803)
1. Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids.
Claypool AL; DiGennaro C; Russell WA; Yildirim MF; Zhang AF; Reid Z; Stringfellow EJ; Bearnot B; Schackman BR; Humphreys K; Jalali MS
JAMA Health Forum; 2023 May; 4(5):e231080. PubMed ID: 37204803
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Treatments for Opioid Use Disorder.
Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK
JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832
[TBL] [Abstract][Full Text] [Related]
3. Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
Adams JW; Savinkina A; Fox A; Behrends CN; Madushani RWMA; Wang J; Chatterjee A; Walley AY; Barocas JA; Linas BP
Addiction; 2022 Oct; 117(10):2635-2648. PubMed ID: 35315148
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder.
Carter JA; Dammerman R; Frost M
J Med Econ; 2017 Aug; 20(8):893-901. PubMed ID: 28604141
[TBL] [Abstract][Full Text] [Related]
5. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Enns B; Krebs E; Whitehurst DGT; Jutras-Aswad D; Le Foll B; Socias ME; Nosyk B;
Drug Alcohol Depend; 2023 Jun; 247():109893. PubMed ID: 37120920
[TBL] [Abstract][Full Text] [Related]
7. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits, and healthcare cost compared to late initiation.
Sun T; Aroke H; Kogut S; Katenka N; Bratberg J; Buchanan A
Am J Drug Alcohol Abuse; 2022 Mar; 48(2):217-225. PubMed ID: 34780312
[No Abstract] [Full Text] [Related]
8. Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis.
Qian G; Humphreys K; Goldhaber-Fiebert JD; Brandeau ML
Drug Alcohol Depend; 2024 Mar; 256():111112. PubMed ID: 38335797
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of buprenorphine vs. methadone for pregnant people with opioid use disorder.
Robin AM; Hersh AR; John C; Caughey AB
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):4918-4926. PubMed ID: 33455473
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder.
Flam-Ross JM; Marsh E; Weitz M; Savinkina A; Schackman BR; Wang J; Madushani RWMA; Morgan JR; Barocas JA; Walley AY; Chrysanthopoulou SA; Linas BP; Assoumou SA
JAMA Netw Open; 2023 Sep; 6(9):e2329583. PubMed ID: 37703018
[TBL] [Abstract][Full Text] [Related]
12. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
13. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
[TBL] [Abstract][Full Text] [Related]
14. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
Connock M; Juarez-Garcia A; Jowett S; Frew E; Liu Z; Taylor RJ; Fry-Smith A; Day E; Lintzeris N; Roberts T; Burls A; Taylor RS
Health Technol Assess; 2007 Mar; 11(9):1-171, iii-iv. PubMed ID: 17313907
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
Murphy SM; McCollister KE; Leff JA; Yang X; Jeng PJ; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Ann Intern Med; 2019 Jan; 170(2):90-98. PubMed ID: 30557443
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effects of Increasing Buprenorphine Treatment Seeking, Duration, and Capacity on Opioid Overdose Fatalities: A Model-based Analysis.
Stringfellow EJ; Lim TY; DiGennaro C; Zhang Z; Paramasivam P; Bearnot B; Humphreys K; Jalali MS
J Addict Med; 2023 Jul-Aug 01; 17(4):439-446. PubMed ID: 37579104
[TBL] [Abstract][Full Text] [Related]
18. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
Nguyen B; Zhao C; Bailly E; Chi W
J Gen Intern Med; 2024 Jan; 39(1):95-102. PubMed ID: 37670069
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.
Barocas JA; Morgan JR; Fiellin DA; Schackman BR; Eftekhari Yazdi G; Stein MD; Freedberg KA; Linas BP
Int J Drug Policy; 2019 Oct; 72():160-168. PubMed ID: 31085063
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of emergency department-initiated treatment for opioid dependence.
Busch SH; Fiellin DA; Chawarski MC; Owens PH; Pantalon MV; Hawk K; Bernstein SL; O'Connor PG; D'Onofrio G
Addiction; 2017 Nov; 112(11):2002-2010. PubMed ID: 28815789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
